WO2017070515A3 - Methods of preventing and treating inflammatory bowel disease with branched fatty acid esters of hydroxy fatty acids (fahfas) - Google Patents

Methods of preventing and treating inflammatory bowel disease with branched fatty acid esters of hydroxy fatty acids (fahfas) Download PDF

Info

Publication number
WO2017070515A3
WO2017070515A3 PCT/US2016/058184 US2016058184W WO2017070515A3 WO 2017070515 A3 WO2017070515 A3 WO 2017070515A3 US 2016058184 W US2016058184 W US 2016058184W WO 2017070515 A3 WO2017070515 A3 WO 2017070515A3
Authority
WO
WIPO (PCT)
Prior art keywords
acid esters
fahfas
preventing
fatty acid
methods
Prior art date
Application number
PCT/US2016/058184
Other languages
French (fr)
Other versions
WO2017070515A2 (en
Inventor
Barbara B. Kahn
Alan Saghatelian
Jennifer Lee
Pedro M. MORAES-VIEIRA
Original Assignee
Beth Israel Deaconess Medical Center, Inc.
Salk Institute For Biological Studies
President And Fellows Of Harvard College
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beth Israel Deaconess Medical Center, Inc., Salk Institute For Biological Studies, President And Fellows Of Harvard College filed Critical Beth Israel Deaconess Medical Center, Inc.
Publication of WO2017070515A2 publication Critical patent/WO2017070515A2/en
Publication of WO2017070515A3 publication Critical patent/WO2017070515A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system

Abstract

The invention provides a method and pharmaceutical composition useful in preventing and treating colitis with branched fatty acid esters of hydroxy fatty acids (FAHFAs). For example, the invention is related to the use of branched palmitic acid esters of hydroxy stearic acids (PAHS As), with beneficial metabolic and anti -inflammatory effects. The composition contains effective amounts of PAHS As and a pharmaceutically acceptable vehicle, carrier and/or diluent. The pharmaceutical compositions are prepared for oral administration in single or combination therapies.
PCT/US2016/058184 2015-10-23 2016-10-21 Methods of preventing and treating inflammatory bowel disease with branched fatty acid esters of hydroxy fatty acids (fahfas) WO2017070515A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562245969P 2015-10-23 2015-10-23
US62/245,969 2015-10-23

Publications (2)

Publication Number Publication Date
WO2017070515A2 WO2017070515A2 (en) 2017-04-27
WO2017070515A3 true WO2017070515A3 (en) 2017-05-26

Family

ID=57249884

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2016/058184 WO2017070515A2 (en) 2015-10-23 2016-10-21 Methods of preventing and treating inflammatory bowel disease with branched fatty acid esters of hydroxy fatty acids (fahfas)

Country Status (1)

Country Link
WO (1) WO2017070515A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150133551A1 (en) 2012-05-03 2015-05-14 Beth Israel Deaconess Medical Center, Inc. Lipids That Increase Insulin Sensitivity And Methods Of Using The Same
WO2014144777A2 (en) 2013-03-15 2014-09-18 Beth Israel Deaconess Medical Center, Inc. Lipids that increase insulin sensitivity and methods of using the same
US11013711B2 (en) 2016-06-10 2021-05-25 Beth Israel Deaconess Medical Center, Inc. Fatty acid esters of hydroxy fatty acids (FAHFAs) for use in the treatment of type 1 diabetes
WO2023031226A1 (en) * 2021-08-31 2023-03-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of branched chain fatty acids (bcfas) for the treatment of intestinal inflammation

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014144777A2 (en) * 2013-03-15 2014-09-18 Beth Israel Deaconess Medical Center, Inc. Lipids that increase insulin sensitivity and methods of using the same

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150133551A1 (en) 2012-05-03 2015-05-14 Beth Israel Deaconess Medical Center, Inc. Lipids That Increase Insulin Sensitivity And Methods Of Using The Same

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014144777A2 (en) * 2013-03-15 2014-09-18 Beth Israel Deaconess Medical Center, Inc. Lipids that increase insulin sensitivity and methods of using the same

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DIGNASS A U ET AL: "Review article: The aetiopathogenesis of inflammatory bowel disease - Immunology and repair mechanisms", ALIMENTARY PHARMACOLOGY AND THERAPEUTICS, SUPPLEMENT 200410 GB, vol. 20, no. 4, October 2004 (2004-10-01), pages 9 - 17, XP055337261, ISSN: 0953-0673 *
LUCA PASTORELLI ET AL: "Central Role of the Gut Epithelial Barrier in the Pathogenesis of Chronic Intestinal Inflammation: Lessons Learned from Animal Models and Human Genetics", FRONTIERS IN IMMUNOLOGY, vol. 4, 1 January 2013 (2013-01-01), XP055337036, DOI: 10.3389/fimmu.2013.00280 *
M. GERSEMANN ET AL: "Innate immune dysfunction in inflammatory bowel disease", JOURNAL OF INTERNAL MEDICINE, vol. 271, no. 5, 13 February 2012 (2012-02-13), GB, pages 421 - 428, XP055337177, ISSN: 0954-6820, DOI: 10.1111/j.1365-2796.2012.02515.x *
YORE MARK M ET AL: "Discovery of a Class of Endogenous Mammalian Lipids with Anti-Diabetic and Anti-inflammatory Effects", CELL, CELL PRESS, US, vol. 159, no. 2, 9 October 2014 (2014-10-09), pages 318 - 332, XP029073421, ISSN: 0092-8674, DOI: 10.1016/J.CELL.2014.09.035 *

Also Published As

Publication number Publication date
WO2017070515A2 (en) 2017-04-27

Similar Documents

Publication Publication Date Title
WO2017070515A3 (en) Methods of preventing and treating inflammatory bowel disease with branched fatty acid esters of hydroxy fatty acids (fahfas)
HRP20160203T1 (en) Compositions comprising 15-hepe and methods of using the same
WO2014167554A3 (en) Composition and formulation of antimicrobial agents, processes thereof and methods for treating microbial infections
NZ742220A (en) Pharmaceutical compositions comprising meloxicam
MX2022010507A (en) Methods of reducing the risk of a cardiovascular event in a subject on statin therapy.
WO2014004861A3 (en) Methods of treating pediatric metabolic syndrome
WO2017053868A8 (en) C4-modified oleanolic acid derivatives for inhibition of il-17 and other uses
WO2018209363A3 (en) Propionic acid derivatives and methods of use thereof
WO2012013331A3 (en) Capsules of active pharmaceutical ingredients and polyunsaturated fatty acids for the treatment of prostate diseases
WO2015104292A3 (en) Compounds for use in treating or preventing cancerous diseases
WO2011097276A8 (en) Methods and compositions for treating arthritis with docosahexaenoic acid
WO2018111315A8 (en) PYRIMIDINE TRICYCLIC ENONE DERIVATIVES FOR INHIBITION OF RORγ AND OTHER USES
WO2015171965A3 (en) Cholix toxin-derived fusion molecules for oral delivery of biologically active cargo
WO2015034678A3 (en) Corticosteroid containing orally disintegrating tablet compositions for eosinophilic esophagitis
MX2015017202A (en) Modified release formulation.
BR112017007428A2 (en) fatty acid and self-fatty acid ester compositions and their uses in the treatment of disease states
WO2014165190A3 (en) Compositions comprising docosapentaenoic acid and methods of use
IL265480A (en) Lipoic acid choline ester compositions and methods to stabilize into pharmaceutically relevant drug products
JP2016513650A5 (en)
WO2017077528A3 (en) Methods and pharmaceutical compositions for treatment of lung inflammation
MY193963A (en) Composition for treating joint diseases and kit containing same
MY169329A (en) Derivative of butylphthalide and preparation method and use thereof
WO2016195194A3 (en) Novel tlr2 antagonists
WO2016149382A3 (en) Compositions and methods for suppressing or reducing systemic immune response in a subject
MX2015010594A (en) Lipobalanced long chain testosterone esters for oral delivery.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 16791738

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 16791738

Country of ref document: EP

Kind code of ref document: A2